WITHDRAWN: Biallelic mutation of SUPV3L1 causes an inherited leukodystrophy-associated neurodevelopmental disorder due to aberrant mitochondrial double stranded RNA processing - Green, Lydia; Hamilton, Noémie; Elpidorou, Marilena; Harris, Erica L.; Douglas, Andrew; Ounap, Katrin; Maroofian, Reza; Rose, Ailsa M.S.; Elworthy, Stone; Renshaw, Stephen A; Low, Elizabeth C.; Prescott, Trine; et al. (medRxiv, 2023)
The authors have withdrawn their manuscript owing to an error identified by the corresponding author. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by a Sir Jules Thorn Award for Biomedical Research (JTA/09 to E.G.S and C.A.J.), a University of Leeds Academic Fellowship (to J.A.P), a University of Leeds PhD studentship (to M.E) and a White Rose Universities Collaboration grant (to N.H. and J.A.P). J.A.P is supported by a UKRI Future Leaders Fellowship (MR/T02044X/1). N.H. is supported by a grant from The Legacy of Angels. S.A.R is supported by a Medical Research Council grant to SHIELD consortium MR/NO2995X/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Yorkshire & Humber Leeds East Research Ethics Committee (REC ref. 18/YH/0070).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes